|
01 Mar 2018 |
Novavax NanoFlu™ Vaccine Demonstrates Improved Immune Responses Compared to Egg-Based, High-Dose Flu Vaccine
|
|
28 Feb 2018 |
Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
|
|
27 Feb 2018 |
Emergent BioSolutions and Valneva initiate phase 1 clinical study to evaluate vaccine candidate against Zika virus
|
|
27 Feb 2018 |
DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk- Allergic Patients
|
|
26 Feb 2018 |
Bavarian Nordic Announces Collaboration to Evaluate CV301 in Combination with durvalumab in Colorectal and Pancreatic Cancers
|
|
22 Feb 2018 |
OncoPep Announces Initiation of Phase 1b Clinical Trial of PVX-410 in Metastatic Triple Negative Breast Cancer
|
|
20 Feb 2018 |
Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy
|
|
19 Feb 2018 |
Results from Innovative Phase 2 Tuberculosis Vaccine Trial Offer Potential for New BCG Revaccination Strategies, Hope For Subunit Vaccines
|
|
13 Feb 2018 |
CureVac to Pursue Innovative mRNA Vaccines Against Flu and Malaria
|
|
13 Feb 2018 |
Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union
|
|
13 Feb 2018 |
Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic Cervical Cancer in the International Journal of Gynecological Cancer
|
|
08 Feb 2018 |
GSK’s meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age
|
|
07 Feb 2018 |
Bavarian Nordic Announces Positive Results of Pivotal Phase 3 Study of IMVAMUNE® Smallpox Vaccine
|
|
06 Feb 2018 |
Argos Obtains Option to License PD1 Checkpoint Inhibitors
|
|
01 Feb 2018 |
Panacea Pharmaceuticals Completes Enrollment in Phase 1 Study of First-in-Class Cancer Vaccine Therapy in Patients with Persistent Prostate Cancer
|
|
01 Feb 2018 |
Vaxart Announces Its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study
|
|
26 Jan 2018 |
GSK’s Shingrix receives positive opinion from the CHMP in Europe for the prevention of shingles in adults aged 50 and over
|
|
25 Jan 2018 |
Araclon Biotech Partners with TFS International for Their Alzheimer’s Phase II Trial
|
|
24 Jan 2018 |
Treos Bio Announces FDA Approval of IND of Its First PolyPEPI™ Precision Cancer Vaccine for Metastatic Colorectal Cancer
|
|
22 Jan 2018 |
Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients
|
|
20 Jan 2018 |
Tonix Pharmaceuticals Announces Publication Reporting Synthesis, Construction and Characterization of a Potential Smallpox-Preventing Vaccine Candidate TNX-801 (Live Horsepox Virus from Cell Culture)
|
|
19 Jan 2018 |
Bavarian Nordic Announces Initiation of Clinical Trial with Novel Cancer Immunotherapy Targeting Brachyury in Cancer Metastasis
|
|
18 Jan 2018 |
VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901
|
|
18 Jan 2018 |
First Chronic Hepatitis B Patient Dosed in China in a Phase 1 Trial of T101 (Transgene’s TG1050 Technology)
|
|
17 Jan 2018 |
First Patient Dosed in a Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC)
|
